Korean J Pain.  2015 Jul;28(3):167-168. 10.3344/kjp.2015.28.3.167.

Risk Factor and Prevention of Postherpetic Neuralgia

• Kim JH

• KMID: 2149459
• DOI: http://doi.org/10.3344/kjp.2015.28.3.167

Abstract

No abstract available.

MeSH Terms

Neuralgia, Postherpetic*
Risk Factors*

Reference

1. Choi WS, Noh JY, Huh JY, Jo YM, Lee J, Song JY, et al. Disease burden of herpes zoster in Korea. J Clin Virol. 2010; 47:325–329. PMID: 20181512.

2. Jung HS, Kang JK, Yoo SH. Epidemiological study on the incidence of herpes zoster in the nearby Cheonan. Korean J Pain. 2015; 28:193–197.

3. Nahm FS, Kim SH, Kim HS, Shin JW, Yoo SH, Yoon MH, et al. Survey on the treatment of postherpetic neuralgia in Korea; multicenter study of 1,414 patients. Korean J Pain. 2013; 26:21–26. PMID: 23342203.

4. Opstelten W, Zuithoff NP, van Essen GA, van Loon AM, van Wijck AJ, Kalkman CJ, et al. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain. 2007; 132(Suppl 1):S52–S59. PMID: 17379412.

5. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology. 2004; 62:1545–1551. PMID: 15136679.

6. Zaal MJ, Volker-Dieben HJ, D'Amaro J. Risk and prognostic factors of postherpetic neuralgia and focal sensory denervation: a prospective evaluation in acute herpes zoster ophthalmicus. Clin J Pain. 2000; 16:345–351. PMID: 11153792.

7. Pica F, Gatti A, Divizia M, Lazzari M, Ciotti M, Sabato AF, et al. One-year follow-up of patients with long-lasting post-herpetic neuralgia. BMC Infect Dis. 2014; 14:556. PMID: 25361823.

8. Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005-2009. J Infect. 2015; 70:178–186. PMID: 25230396.

9. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007; 44(Suppl 1):S1–S26. PMID: 17143845.

10. Jeon Y. Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment. Korean J Pain. 2015; 28:177–184.

11. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996; 22:341–347. PMID: 8838194.

12. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing post-herpetic neuralgia. A meta-analysis. Arch Intern Med. 1997; 157:909–912. PMID: 9129551.

13. Kumar V, Krone K, Mathieu A. Neuraxial and sympathetic blocks in herpes zoster and postherpetic neuralgia: an appraisal of current evidence. Reg Anesth Pain Med. 2004; 29:454–461. PMID: 15372391.

14. Kim KH. Herpes zoster vaccination. Korean J Pain. 2013; 26:242–248. PMID: 23861997.

15. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012; 54:922–928. PMID: 22291101.

16. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005; 352:2271–2284. PMID: 15930418.